Related Experiment Video
Updated: Dec 6, 2025
08:41
Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2
Published on: November 5, 2021
3.1K
Sarilumab use in severe SARS-CoV-2 pneumonia
Elisa Gremese1,2, Antonella Cingolani3,4, Silvia Laura Bosello1
1Fondazione Policlinico Universitario A. Gemelli IRCCS, UOC di Reumatologia, Rome, Italy.
Eclinicalmedicine
|October 12, 2020
Summary
Interleukin-6 receptor (IL-6R) blockade with Sarilumab shows promise for severe COVID-19 pneumonia. This study indicates Sarilumab improves patient outcomes and demonstrates a good safety profile in hospitalized patients.
Area of Science:
- Immunology
- Virology
- Critical Care Medicine
Background:
- Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can cause severe pneumonia and respiratory distress.
- Interleukin-6 (IL-6) signaling blockade has shown preliminary efficacy in managing the inflammatory response associated with SARS-CoV-2.
- Off-label intravenous use of Sarilumab was investigated in patients with severe SARS-CoV-2 pneumonia.
Purpose of the Study:
- To evaluate the clinical outcomes and safety of intravenous Sarilumab in patients with severe SARS-CoV-2 pneumonia.
- To assess pulmonary function improvement, Intensive Care Unit (ICU) admission rates, and discharge rates in patients treated with Sarilumab.
Main Methods:
- A total of 53 patients with SARS-CoV-2 severe pneumonia received intravenous Sarilumab (400 mg initially, with potential additional infusions).
- Patients were monitored for pulmonary function, ICU admission, hospital discharge, and safety.
- Follow-up was conducted for at least 14 days post-treatment or until discharge/death.
Main Results:
- In medical wards (39 patients), 89.7% improved, 70.6% were discharged, and 85.7% no longer required oxygen therapy.
- In the ICU (14 patients), 64.2% were discharged to the ward, and 35.8% remained alive at follow-up.
- The overall mortality rate was 5.7%.
Conclusions:
- Interleukin-6 receptor (IL-6R) inhibition with Sarilumab is a potential therapeutic strategy for severe SARS-CoV-2 pneumonia.
- Intravenous Sarilumab demonstrated significant short-term clinical benefits and a favorable safety profile.
- Sarilumab represents a promising treatment option for managing severe COVID-19-related respiratory illness.
Related Concept Videos
01:28Pneumonia IV: Management
629
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
629
01:26Pulmonary Tuberculosis IV
309
Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
309
01:21Acute Respiratory Failure-II
837
Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
837
01:26COPD: Management Using Bronchodilators and Corticosteroids
596
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
596
01:03Rous Sarcoma Virus (RSV) and Cancer
5.9K
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
5.9K
01:19Antiasthma Drugs: Leukotriene Modifiers
1.6K
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
1.6K